Axis Capital said the company’s chemical business offers healthy medium-term growth potential and expects a 23% CAGR in this segment over FY25 to FY28.
Axis Capital said the company’s chemical business offers healthy medium-term growth potential and expects a 23% CAGR in this segment over FY25 to FY28.